Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease

[1]  P. Serruys,et al.  Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease , 2021, European heart journal.

[2]  A. Roguin,et al.  Impact of pre-existent vascular and poly-vascular disease on acute myocardial infarction management and outcomes: An analysis of 2 million patients from the National Inpatient Sample. , 2020, International journal of cardiology.

[3]  V. Fuster,et al.  Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation , 2020, The Lancet.

[4]  R. Jaffe,et al.  Effect of Cerebrovascular and/or Peripheral Artery Disease With or Without Attainment of Lipid Goals on Long-Term Outcomes in Patients With Coronary Artery Disease. , 2020, The American journal of cardiology.

[5]  P. K. Sharma.  Atherosclerosis. , 2020, The Journal of the Association of Physicians of India.

[6]  P. Serruys,et al.  Impact of established cardiovascular disease on outcomes in the randomized global leaders trial , 2019, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[7]  Manesh R Patel,et al.  Polyvascular Disease: Reappraisal of the Current Clinical Landscape. , 2019, Circulation. Cardiovascular interventions.

[8]  P. Kolh,et al.  Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial , 2019, The Lancet.

[9]  W. Aronow.  Faculty Opinions recommendation of Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[10]  P. Serruys,et al.  Quantitative aortography for assessing aortic regurgitation after transcatheter aortic valve implantation: results of the multicentre ASSESS-REGURGE Registry. , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[11]  P. Libby,et al.  Atherosclerosis , 2019, Nature Reviews Disease Primers.

[12]  Deepak L. Bhatt,et al.  Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial. , 2019, Journal of the American College of Cardiology.

[13]  Lehana Thabane,et al.  An introduction to multiplicity issues in clinical trials: the what, why, when and how. , 2016, International journal of epidemiology.

[14]  S. Yajima,et al.  Symptomatic peripheral artery disease is associated with decreased long-term survival after coronary artery bypass: a contemporary retrospective analysis , 2016, Surgery Today.

[15]  J. McMurray,et al.  Statistical Controversies in Reporting of Clinical Trials: Part 2 of a 4-Part Series on Statistics for Clinical Trials. , 2015, Journal of the American College of Cardiology.

[16]  V. Fuster,et al.  Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study , 2015, Circulation.

[17]  J. Spertus,et al.  Rethinking Composite End Points in Clinical Trials: Insights From Patients and Trialists , 2014, Circulation.

[18]  H. Nathoe,et al.  The impact of polyvascular disease on long‐term outcome in percutaneous coronary intervention patients , 2014, European journal of clinical investigation.

[19]  M. Onoe,et al.  Impact of polyvascular disease on clinical outcomes in patients undergoing coronary revascularization: an observation from the CREDO-Kyoto Registry Cohort-2. , 2013, Atherosclerosis.

[20]  Antonio Colombo,et al.  Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial , 2013, The Lancet.

[21]  Deepak L. Bhatt,et al.  Polyvascular Disease and Long-Term Cardiovascular Outcomes in Older Patients With Non–ST-Segment–Elevation Myocardial Infarction , 2012, Circulation. Cardiovascular quality and outcomes.

[22]  M. Matsuzaki,et al.  Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial. , 2011, Atherosclerosis.

[23]  Deepak L. Bhatt,et al.  Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.

[24]  A. Algra,et al.  Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study , 2010, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[25]  Antonio Colombo,et al.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.

[26]  Paul M Ridker,et al.  Inflammation in atherosclerosis: from pathophysiology to practice. , 2009, Journal of the American College of Cardiology.

[27]  Deepak L. Bhatt,et al.  Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry , 2009, European heart journal.

[28]  Deepak L. Bhatt,et al.  Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. , 2009, European heart journal.

[29]  C. Binz,et al.  Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort , 2009, Clinical Research in Cardiology.

[30]  Patrick W Serruys,et al.  The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. , 2006, American heart journal.

[31]  Deepak L. Bhatt,et al.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.

[32]  P. Rothwell.  Subgroup analysis in randomised controlled trials: importance, indications, and interpretation , 2005, The Lancet.

[33]  D. Malenka,et al.  Survival in patients with peripheral vascular disease after percutaneous coronary intervention and coronary artery bypass graft surgery. , 2004, The Annals of thoracic surgery.

[34]  E J Topol,et al.  Cause of death in clinical research: time for a reassessment? , 1999, Journal of the American College of Cardiology.

[35]  M. A. Sellers,et al.  Long-term prognostic value of clinically evident noncoronary vascular disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). , 1998, The American journal of cardiology.

[36]  B. Gersh,et al.  Long-term survival in patients with coronary artery disease: Importance of peripheral vascular disease , 1994 .

[37]  M. Nobuyoshi,et al.  Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[38]  B. Gersh,et al.  Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) Investigators. , 1994, Journal of the American College of Cardiology.